TSHA
Taysha Gene Therapies Inc
4.50$
-3.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | – | -3,532.8% | -472.6% | -974.7% | -952.5% | |
| – | – | – | 46.8% | 8.9% | 14.9% | 11.7% | |
| – | – | – | 721.1% | 51.2% | 157.2% | 136.1% | |
| – | – | – | 2,315.5% | – | – | – | |
| – | – | – | 740.1% | -116.6% | -149.6% | -55.0% | |
| – | – | – | 994.0% | 47.7% | 4.5% | 7.6% | |
| – | – | – | -996.4% | -47.6% | -4.4% | -6.2% | |
| – | – | – | 0.0% | -22.3% | 0.0% | 94.6% | |
| – | – | – | 2,082.2% | 882.7% | 920.2% | 2,809.7% | |
| – | – | – | -2,447.0% | 362.6% | -58.9% | 1,851.0% | |
| – | – | – | -4,526.7% | -520.3% | -979.2% | -960.1% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.